INTRODUCTION {#s1}
============

Ovarian cancer (OC) is the major cause of death among gynecological cancer entities \[[@R1]\]. In recent years, multidisciplinary treatment options including surgery, chemotherapy regimens and anti-angiogenic agents have considerably evolved \[[@R2]\], however, long term prognosis for OC patients remains devastating \[[@R3]\]. Therefore, therapies targeting tumor immunogenicity and anti-tumor immunity \[[@R4]\] such as antibodies that inhibit checkpoint molecules, i.e. the programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) pathway \[[@R5]\] have recently gained attention as a novel therapeutic option in OC \[[@R6]\].

PD-L1 is expressed by tumor cells \[[@R7]\] to inactivate T-cells via binding to PD-1 \[[@R8]\] and escape from the immune system \[[@R7]\]. Checkpoint (i.e. PD-1/PD-L1) inhibitors can restore T-cell mediated tumor immunogenicity and have been successfully established in anti-tumor treatment \[[@R9]\]. Ongoing clinical trials investigate whether PD-1/PD-L1 inhibitors can be an effective treatment option for patients with OC.

The rationale to test the efficacy of checkpoint inhibitors in OC arises from the observation that intratumoral T-cells directly correlate with clinical outcome \[[@R10]\] and that the PD-1/PD-L1 pathway may play a relevant role in the immune evasion of malignant ovarian tumors \[[@R11]\]. Clinical trials with immune checkpoint inhibitors were performed in patients with advanced and recurrent OC and demonstrated response rates of ∼15% \[[@R6]\]. Thus, checkpoint inhibitors may improve clinical outcome in a subgroup of OC patients, but predictors of response or identification of patients who benefit are urgently needed.

In the present study we, therefore, systematically analyzed *PD-1* and *PD-L1* mRNA expression in 170 epithelial OC in relation to 28 non-neoplastic tissues and to clinicopathological features to identify a subgroup of patients which may profit by checkpoint inhibitors. Since *IFNγ* was found to play an essential role in the adaptive immune resistance of tumors as an inducer of *PD-L1* on tumor cells \[[@R12]\], i.e. on ovarian cancer cells *in vitro* \[[@R13]\], we further performed correlation analyses between *IFNγ* and *PD-1* or *PD-L1* to investigate the regulative role of the PD-1 pathway in OC. Previous studies demonstrate that tumors with high mutational burdens exhibit a greater response rate to immune checkpoint blockade \[[@R14]--[@R16]\]. Based on these observations we further stratified our analysis by *BRCA1/2* and *TP53* mutation status.

RESULTS {#s2}
=======

*PD-1* expression is elevated in OC tissue and fallopian tubes {#s2_1}
--------------------------------------------------------------

To evaluate the potential regulative power of the PD-1 pathway in OC, we analyzed mRNA expression levels in cancer tissue and non-neoplastic ovaries and fallopian tubes. We determined strong *PD-1* expression in cancer tissue compared to non-cancer tissues (OC vs non-neoplastic ovaries: *p* \< 0.001; OC vs. non-neoplastic tubes: *p* = 0.018; Figure [1A](#F1){ref-type="fig"}). We further found higher expression of *PD-1* in non-neoplastic tubes compared to non-neoplastic ovaries (*p* = 0.031; Figure [1A](#F1){ref-type="fig"}). However, we did not note increased *PD-L1* expression in OC tissue compared to non-neoplastic tissues (Figure [1B](#F1){ref-type="fig"}). Detection of PD-L1 by immunohistochemistry was associated with increased *PD-L1* expression determined by qPCR in non-malignant tissues ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![*PD-1* mRNA expression is elevated in OC tissue compared to non-neoplastic ovaries and fallopian tubes\
(**A**) *PD-1* expression in non-neoplastic fallopian tubes, non-neoplastic ovaries and OC. (**B**) *PD-L1* expression in non-neoplastic fallopian tubes, non-neoplastic ovaries and OC. *PD-1* and *PD-L1* mRNA expression values were normalized to *TBP* expression.](oncotarget-09-17501-g001){#F1}

*PD-1* and *PD-L1* mRNA expression strongly correlates with *IFNG* mRNA expression {#s2_2}
----------------------------------------------------------------------------------

Performing Spearman rank association analyses of 170 OC tissues, we noted a significant correlation of *PD-1* with *PD-L1* expression (*p* \< 0.001; r~S~ = 0.593). We further found a strong correlation between *IFNG* mRNA expression with both *PD-1* (*p* \< 0.001; r~S~ = 0.707) and *PD-L1* (*p* \< 0.001; r~S~ = 0.741). This was similarly demonstrable in our log-transformed data set with Pearson correlation analyses (Figure [2](#F2){ref-type="fig"}). These correlations were also detected in control tissues (data not shown).

![Correlation of *PD-1* and *PD-L1* mRNA expression with *IFNG* mRNA expression in 170 OC tissues\
Linear regression analysis of (**A**) *PD-1* and *PD-L1*, (**B**) *PD-1* and *IFNG* and (**C**) *PD-L1* and *IFNG*. *PD-1*, *PD-L1* and *IFNG* mRNA expression values were normalized to *TBP* expression.](oncotarget-09-17501-g002){#F2}

Increased *PD-1* and *PD-L1* mRNA expression occurred in young patients and high tumor grade {#s2_3}
--------------------------------------------------------------------------------------------

Next, we analyzed *PD-1* and *PD-L1* mRNA expression according to clinical and histopathological characteristics. We noted increasing *PD-L1* expression in younger (\< median age of 60.4 years) patients (*p* = 0.001; Table [1A](#T1){ref-type="table"}). Furthermore, *PD1* and *PD-L1* expression progressed with tumor grade (*p* = 0.008 and *p* = 0.027, respectively; Table [1A](#T1){ref-type="table"}).

###### Association of *PD-1* and *PD-L1* mRNA expression with clinicopathological features in ovarian cancer patients.

Analysis in (**A**) all 170 ovarian cancer patients, (**B**) only HGSOC patients (*N* =106) and (**C**) only HGSOC, FIGO III/IV patients (*N* = 85)

  \(A\) All tumors                                                                               
  ---------------------- ------------- ----- ------ ------------ ----------- ------ ------------ -----------
  **Age (median)**       ≤60.4 yrs.    85    0.12   0.07--0.34   0.128       0.47   0.27--0.76   **0.001**
                         \>60.4 yrs.   85    0.13   0.05--0.21               0.32   0.16--0.53   
  **FIGO stage**         I             38    0.11   0.05--0.32   0.350       0.38   0.15--0.68   0.563
                         II            13    0.10   0.05--0.51               0.33   0.20--1.01   
                         III           102   0.12   0.06--0.21               0.37   0.22--0.58   
                         IV            17    0.23   0.13--0.39               0.51   0.25--0.95   
  **Tumor grade**        1             12    0.10   0.06--0.17   **0.008**   0.38   0.24--0.47   **0.027**
                         2             81    0.10   0.04--0.20               0.32   0.17--0.51   
                         3             77    0.16   0.08--0.37               0.47   0.23--0.78   
  **Residual disease**   no            78    0.11   0.04--0.23   0.113       0.35   0.17--0.58   0.090
  **after surgery**      yes           87    0.14   0.08--0.31               0.45   0.24--0.70   
                         unknown       5                                                         
  **Histology**          HGSOC         106   0.12   0.05--0.22   0.219       0.33   0.20--0.59   0.131
                         LGSOC         11    0.09   0.06--0.15               0.38   0.23--0.42   
                         endometroid   43    0.14   0.05--0.38               0.49   0.20--0.68   
                         clear cell    10    0.28   0.07--0.42               0.60   0.36--1.07   

  \(B\) HGSOC                                                                               
  ---------------------- ------------- ---- ------ ------------ ------- ------ ------------ -----------
  **Age (median)**       ≤60.9 yrs.    53   0.11   0.05--0.27   0.451   0.46   0.24--0.75   **0.004**
                         \>60.9 yrs.   53   0.13   0.04--0.19           0.28   0.15--0.44   
  **FIGO stage**         I             14   0.12   0.05--0.29   0.213   0.24   0.11--0.91   0.157
                         II            7    0.07   0.05--0.37           0.33   0.19--1.24   
                         III           71   0.10   0.05--0.19           0.32   0.20--0.51   
                         IV            14   0.21   0.14--0.30           0.54   0.34--0.94   
  **Residual disease**   no            37   0.10   0.04--0.20   0.200   0.27   0.14--0.54   0.062
  **after surgery**      yes           64   0.13   0.07--0.26           0.39   0.24--0.63   
                         unknown       5                                                    

  \(C\) Only HGSOC, FIGO III/IV                                                                          
  ------------------------------- ------------- ---- ------ ------------ ----------- ------ ------------ -----------
  **Age (median)**                ≤59.2 yrs.    43   0.12   0.06--0.24   0.499       0.47   0.24--0.70   **0.021**
                                  \>59.2 yrs.   42   0.13   0.04--0.19               0.31   0.20--0.45   
  **FIGO stage**                  III           71   0.10   0.05--0.19   **0.031**   0.32   0.20--0.51   **0.031**
                                  IV            14   0.21   0.14--0.30               0.54   0.34--0.94   
  **Residual disease**            no            19   0.05   0.03--0.19   0.063       0.27   0.16--0.51   0.100
  **after surgery**               yes           61   0.13   0.08--0.25               0.40   0.24--0.63   
                                  unknown       5                                                        

Note: The significance level (P) was determined by Mann--Whitney U or Kruskal--Wallis test respectively.

Abbreviations: HGSOC, high-grade serous ovarian cancer; IQR, Interquartile range; LGSOC, low-grade serous ovarian cancer.

*PD-1* and *PD-L1* mRNA expression is elevated in FIGO IV OC {#s2_4}
------------------------------------------------------------

When analyzing the subgroup of patients suffering from HGSOC (Table [1B](#T1){ref-type="table"}) we further observed a tendency of higher *PD-L1* levels in patients with residual disease after primary debulking operation (Table [1B](#T1){ref-type="table"}) as compared to patients with no macroscopic disease after upfront debulking. In advanced stage HGSOC higher *PD-1* and *PD-L1* mRNA expression was observed in tissues of stage IV when compared to stage III (*p* = 0.031, Table [1C](#T1){ref-type="table"}).

*BRCA1*/*2* and TP53 mutated tumors are associated with high *PD-1* and *PD-L1* levels {#s2_5}
--------------------------------------------------------------------------------------

In 158 patients from our cohort, mutation analysis data for *BRCA1, BRCA2 and TP53,* genes known to account for OC, were available. We analyzed these cases for the association between gene mutations and *PD-1* and *PD-L1* expression. In 37 of these 158 (23.4%) OC cases, *BRCA1* or *BRCA2* (*BRCA1/2*) mutations were detected. In *BRCA1*/*2* mutated tumors, we found significant higher levels of *PD-1* (*p* = 0.024; Figure [3A](#F3){ref-type="fig"}) and *PD-L1* (*p* = 0.012; Figure [3B](#F3){ref-type="fig"}) compared to *BRCA1/2* wild-type tumors. We were unable to detect differences between *BRCA1* aberrations such as c.4183C\>T and c.1687C\>T which were mostly enriched in our cohort (data not shown). In 91 of 158 OC cases (57.2%) *TP53* mutations were detected. These tumors exhibited higher *PD-L1* levels compared to tumors with wild type *TP53* (*p* = 0.028; Figure [3C](#F3){ref-type="fig"}). A subgroup analysis revealed that these effects in mutated OC were only observed in HGSOC ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}), but not in non-HGSOC cases (data not shown).

![*PD-1* and *PD-L1* mRNA expression according to genetic aberrations\
*BRCA1/2* mutation data in association with (**A**) *PD-1* expression and (**B**) with *PD-L1* expression. (**C**) *TP53* mutation data in association with *PD-L1* expression. Expression values were normalized to *TBP* expression.](oncotarget-09-17501-g003){#F3}

High *PD-1* mRNA expression is associated with a poor prognosis {#s2_6}
---------------------------------------------------------------

We tested whether intratumoral *PD-1* or *PD-L1* expression was associated with clinical outcome. Therefore, we identified the optimal threshold for "high" and "low" expression using Youden's index \[[@R17]\]. In the entire cohort, we could not observe a prognostic relevance of "*PD-1* high" or "*PD-1* low" expressing tumors (Table [2](#T2){ref-type="table"}). However, when we analyzed patients with FIGO III/IV HGSOC, "*PD-1* high" expressing tumors were associated with significantly worse PFS (*p* = 0.024; Figure [4A](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}) when compared to "*PD-1* low" expressing tumors. More specifically, the median time to progression was 15.6 and 24.6 months for patients with "high" and "low" *PD-1* expression, respectively. Patients with "*PD-L1* high" expressing tumors exhibited a significant worse OS compared to patients with "*PD-L1* low" expressing tumors (*p* = 0.049; Figure [4B](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The median OS was 41.1 and 47.1 months for patients with "*PD-1* high" and "*PD-1* low" expressing tumors, respectively. However, the prognostic relevance of *PD-1* or *PD-L1* could not be confirmed in the multivariate Cox regression analyses (data not shown).

###### Univariate survival analysis in 170 ovarian cancer patients. The optimal cutoff points for *PD-1* and *PD-L1* were calculated by the Youden's index

  Variable                                           Progression free Survival   Overall Survival                                                 
  ------------------------------------ ------------- --------------------------- ------------------- ------------- -------- --------------------- -------------
  **Age (median)**                     ≤60.4 yrs.    51/85                       45.5 (19.9--71.2)   0.685         48/85    107.2 (94.6--119.7)   **0.005**
                                       \>60.4 yrs.   45/85                       22.1 (8.2--35.9)                  61/85    43.5 (33.4--53.6)     
  **FIGO stage**                       I/II          11/51                       n.r.                **\<0.001**   20/51    n.r.                  **\<0.001**
                                       III/IV        85/119                      20.0 (14.7--25.3)                 89/119   47.3 (26.6--68.0)     
  **Tumor grade**                      1/2           47/93                       48.8 (0.0--101.6)   0.110         53/93    100.0 (70.1--129.9)   **0.012**
                                       3             49/77                       23.6 (12.6--34.7)                 56/77    44.4 (30.4--58.5)     
  **Residual disease after surgery**   no            24/78                       n.r.                **\<0.001**   30/78    n.r.                  **\<0.001**
                                       yes           68/87                       15.7 (13.2--18.3)                 76/87    35.2 (24.4--46.1)     
  **Histology**                        HGSOC         69/106                      23.4 (17.4--29.4)   **0.008**     80/106   47.1 (27.5--66.7)     **0.003**
                                       others        27/64                       n.r.                              29/64    132.7 (n.r.)          
  **PD-1 mRNA expression**             low           63/118                      35.3 (14.2--56.5)   0.597         30/50    68.8 (0.0--140.8)     0.633
                                       high          33/52                       23.4 (12.1--34.7)                 79/120   71.1 (43.6--98.6)     
  **Subgroup:**                        low           40/69                       24.6 (2.5--46.7)    0.286         24/36    45.6 (0.0--100.2)     0.212
  **HGSOC**                            high          29/37                       20.0 (13.0--27.0)                 56/70    47.1 (33.0--61.2)     
  **Subgroup:**                        low           23/38                       24.6 (0.0--53.1)    **0.024**     16/25    45.6 (0.0--129.2)     0.088
  **HGSOC, FIGO III/IV**               high          40/47                       15.6 (11.0--20.2)                 52/60    44.4 (34.9--53.9)     
  **PD-L1 mRNA expression**            low           44/88                       32.1 (6.2--58.0)    0.872         52/88    68.8 (20.0--117.7)    0.773
                                       high          52/82                       30.0 (6.2--53.7)                  57/82    74.9 (42.0--107.9)    
  **Subgroup:**                        low           28/55                       22.8 (0.0--51.4)    0.202         33/54    49.6 (18.2--81.1)     0.094
  **HGSOC**                            high          41/51                       23.4 (18.0--28.9)                 47/52    44.4 (33.6--55.2)     
  **Subgroup:**                        low           24/42                       18.2 (7.8--28.6)    0.159         26/41    47.1 (14.0--80.2)     **0.049**
  **HGSOC, FIGO III/IV**               high          39/43                       21.8 (14.4--29.2)                 42/44    41.1 (32.6--49.7)     

Note: The significance level (P) was determined by log-rank test.

Abbreviations: n.r., not reached.

![Kaplan--Meier survival analyses and *PD-1* and *PD-L1* mRNA-expression in 85 HGSOC, FIGO III/IV patients\
(**A**) *PD-1* mRNA expression and progression free survival. (**B**) *PD-L1* mRNA expression and overall survival.](oncotarget-09-17501-g004){#F4}

DISCUSSION {#s3}
==========

In this study, we investigated the expression of checkpoint molecules in a Caucasian OC cohort. We found that *TP53* and *BRCA1/2* mutated OC was associated with high *PD-1* and *PD-L1* expression. Both, *PD-1* and *PD-L1* expression correlated with *IFNG* which is known to induce checkpoint molecules in OC cells \[[@R13]\]. We also noted that young women and patients with advanced OC exhibited increased expression of *PD-1* and *PD-L1* which was associated with poor clinical outcome.

Mutations in *BRCA1/2* and *TP53* confer a significant lifetime risk for OC and are considered a major driver of tumorigenesis \[[@R18]\]. Tumors that exhibit these mutations usually present a high neoantigen load \[[@R19]\]. In our cohort, we demonstrate that *BRCA1*/*2* mutated tumors exhibit high *PD-1* and *PD-L1* levels supporting the notion that *BRCA1/2*-mutated tumors may be more sensitive to PD-1/PD-L1 inhibitors compared to wild-type tumors \[[@R19]\] and that the combination therapy of checkpoint inhibitors with poly (ADP-ribose) polymerase (PARP) inhibitors may be more successful \[[@R19]\]. Consistent with previous data we found *TP53* mutations in 66% of HGSOC which is within the range of 50--80% as previously reported \[[@R20]\]. In line with previous studies on lung adenocarcinoma \[[@R21]\] we found that *TP53* mutated tumors showed higher *PD-L1* expression compared to *TP53* wild-type tumors. Dong *et al.* suggested that *TP53* mutated lung adenocarcinomas with increased mutation burden showed remarkable clinical benefit to PD-1 inhibitors \[[@R21]\]. In line with these results, we suggest that the *TP53* mutation status can be used as a potential surrogate predicting treatment response in patients receiving anti-PD-1/PD-L1 immunotherapy.

Checkpoint molecule expression is known to be a negative predictor for clinical outcome in various cancer entities \[[@R22]\]. The available data on the prognostic significance of *PD-1* and *PD-L1* expression in OC are inconsistent. We found that patients with FIGO III/IV HGSOC and "*PD-L1* high" expressing tumors exhibited worse OS when compared to patients with "*PD-L1* low" expressing tumors. Our findings are in line with the recent report by Hamanishi *et al.* who demonstrated that the engagement of the PD-1 pathway (i.e. *PD-L1* expression) is associated with a poor prognosis in OC patients \[[@R11]\]. In contrast, Darb-Esfahani *et al.* demonstrated a favorable prognosis for HGSOC patients with immunohistochemically or transcriptionally high PD-1 and PD-L1 expression in lymphocytes and cancer cells, respectively \[[@R23]\]. Another study by Webb *et al.* also demonstrated that immunohistochemical PD-L1 labeling (primarily of macrophages) correlated with lymphocytic infiltration and improved survival in patients with HGSOC \[[@R24]\]. In other tumor entities such as lung cancer, colorectal cancer and melanoma, *PD-L1* expression was shown to have both positive and negative prediction value which may be due to the following reasons \[[@R22]\]: Primer-based detection of *PD-1* and *PD-L1* has technical issues, such as variable primer sequences, tissue preparation, processing variability or different statistical cut-offs resulting in misleading expression status. Furthermore, *PD-1* and *PD-L1* expression in tumors is affected by temporal (i.e. infections, co-medication such as corticosteroids) and spatial factors, leading to erroneous interpretation of the results. However, our data indicate that high *PD-1* or *PD-L1* expression are negative prognosticators in OC in line with observations of various other tumor entities \[[@R25]--[@R27]\].

Mechanistically, PD-L1 expression was shown to be induced by IFNγ stimulation in mammalian OC cells thereby triggering a negative feedback on T cell activity \[[@R13]\]. This study extensively investigated IFNγ-dependent upregulation of PD-L1 on OC cells. They examined PD-L1 expression on several human and mouse ovarian cancer cell lines by flow cytometry: First, the SK-OV-3 and OVCA429 human OC cell lines already express high levels of PD-L1 at baseline, while the OVARY1847 human OC cell line strongly expressed PD-L1 after exposure to human recombinant IFNγ. Furthermore, the injection of IFNγ into tumours induced PD-L1 expression and promoted tumour growth, while PD-L1 inhibition abrogated tumour growth. In agreement with these findings, we found a strong positive correlation between *IFNG* and *PD-L1* and also *PD-1* expression in human OC. These data support the idea that IFNγ released by the tumor microenvironment may be involved in tumor immune escape \[[@R28]\], possibly via the upregulation of checkpoint molecules \[[@R13]\]. Given that we further found a positive correlation between *IFNG*, *PD-L1* and *PD-1* in non-malignant tissue (data not shown) it appeared that IFNγ regulated PD-1 and PD-L1 expression independent of benign, inflamed or malignant conditions as demonstrated previously \[[@R29], [@R30]\]. However, we suggest that checkpoint molecule expression and tumor escape mechanisms are highly relevant in the latter condition as demonstrated by above mentioned studies \[[@R7], [@R12]\].

As our findings were based on mRNA expression determined by qPCR, we aimed at verifying that transcription correlated with translation of checkpoint molecules in our cohort. Histologically ∼80% of the analyzed OC tissue were composed of cancer cells which led us to conclude that *PD-L1* expression mostly originated from malignant OC cells. While we observed an association between *PD-L1* mRNA and protein expression in non-malignant tissues, we did not observe such association in OC (data not shown). This may be explained by intra-tumor heterogeneity and the technical issue of sample preparation for qPCR and immunohistochemistry analysis from two different sites of the tumor in our study. As a direct relationship between *PD-L1* mRNA and protein expression was not demonstrable in OC, and immunohistochemistry only allows protein quantification to a limited extent, we analyzed clinical characteristics with the results from qPCR expression. However, based on the association between *PD-L1* RNA expression and protein level from non-malignant tissue, we believe that qPCR is a reliable tool for our analyses \[[@R31]\]. We were unable to determine PD-1 protein expression by immunohistochemistry due to lack of available antibodies that yielded a specific signal in our laboratory.

While we demonstrated that *PD-1* expression is significantly higher in OC compared to non-neoplastic ovaries and Fallopian tubes, we did not observe increased *PD-L1* mRNA expression in cancer tissue compared to non-diseased ovaries or tubes. Increased *PD-1* expression may be explained by a study from Webb *et al.* which demonstrated limited PD-1 protein expression on infiltrating lymphocytes in healthy fallopian tubes, but strong PD-1 expression in tumor infiltrating lymphocytes in OC tissue \[[@R32]\]. In contrast, PD-L1 is a cell surface protein that is not only expressed by tumor cells but also by activated antigen-presenting cells which may affect *PD-L1* expression of non-malignant tissues \[[@R30]\]. For example, Maine *et al.* demonstrated that *PD-L1* is strongly expressed on ascites-derived monocytes \[[@R33]\]. We acknowledge that the authors in this study observed increased PD-L1 expression in OC compared to healthy controls which is not demonstrable in our cohort.

In summary, *PD-1* and *PD-L1* expression emerged as critical determinant of OC progression especially in young patients (i.e. \< median age of 60.4 years) with *BRCA1/2* or *TP53* mutated OC. These findings suggest an involvement of checkpoint regulation in OC progression. Our data may guide OC treatment by check point inhibition in the future \[[@R34]\].

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

Ovarian tissue samples from 170 patients with OC obtained at primary debulking (patients were 24 to 90 years old; median age at diagnosis was 60 years) and control tissues from 28 patients obtained by elective salpingo-oophorectomy for benign conditions (14 non-neoplastic tubal tissues: patients were 30 to 73 years old, median age: 50 years; 14 non-neoplastic ovaries: patients were 33 to 74 years old, median age: 57 years) were collected and processed at the Department of Obstetrics and Gynecology of the Medical University of Innsbruck, Austria between 1989 and 2010 as described recently \[[@R35]\]. Written informed consent was obtained from all patients before enrolment. The study was reviewed and approved by the Ethics committee of the Medical University of Innsbruck (reference number: AN2016-0024 358/4.13) and conducted in accordance with the Declaration of Helsinki. All samples were anonymized before the commencement of the analysis. All patients were monitored within the outpatient follow-up program of our department. The median observation period was 5.5 years (0.1 to 26.1). All patients were of Caucasian ethnicity. Clinicopathological features are shown in Table [1](#T1){ref-type="table"}.

RNA isolation and reverse transcription {#s4_2}
---------------------------------------

Total cellular RNA extraction and reverse transcription were performed as previously described \[[@R35]\].

Quantitative real time PCR {#s4_3}
--------------------------

Primers and probes for the TATA box-binding protein (*TBP*; endogenous RNA-control) were used according to *Bieche et al.* \[[@R36]\]. Primers and probes for *PD-L1* (*CD274*) \[GenBank: NM_014143.3\] were determined with the assistance of the computer program Primer Express (Life Technologies, Carlsbad, CA, USA). BLASTN searches were conducted to confirm the total gene specificity of the nucleotide sequences chosen for the primers and probes. *PD-L1* forward primer: 5′-AATGATGGATGTGAAAAAATGTGG-3′; *PD-L1* reverse-primer: 5′-AATGCTGGATTACGTCTCCTCC-3′; *PD-L1* TaqMan probe: 5′-FAM-TCCAAGATACAAACTCAAAGAAGCAAAGTGATACACATT-3′-TAMRA. To prevent amplification of contaminating genomic DNA, the probe was placed at the junction between exons 6 and 7. Primers and probe for *IFNG* and *PD-1* were purchased from Applied Biosystems (Foster City, CA, USA, Applied Biosystems Assay ID: Hs00174143_m1 and Hs01550088_m1). PCR reactions were performed as previously described \[[@R35]\].

Immunohistochemistry {#s4_4}
--------------------

Serial sections of the paraffin embedded material were cut at 2 µm and further processed using a BenchMark™ Ultra automated stainer (Roche Ventana). For the particular primary antibodies the following procedures were used: PD-L1 (clone 28-8; Abcam) diluted at 1:100 was incubated for 32 minutes and the OptiView™ DAB detection kit system CC1 was used for 36 minutes. PD-1 (clone NAT 105; Cell Marque AK) ready to use incubated for 32 minutes followed by the UltraView™ DAB detection kit CC2 for 44 minutes. For counterstaining hematoxylin was used. The evaluation of immunohistochemistry was performed semiquantitatively.

Mutation analysis {#s4_5}
-----------------

Genomic DNA from 158 pulverized, quick-frozen OC specimens was isolated using the DNeasy tissue-kit (Qiagen, Hilden, Germany). Targeted NGS was performed using the TruSight Cancer sequencing panel (Illumina, San Diego, USA). The analyses were performed on the Illumina MiSequ^®^ and the NextSeq system (Illumina, CA, USA). After sequencing, mutations in *BRCA1, BRCA2* and *TP53* were identified with the help of NextGene and Geneticist Assistant softwares. Pathogenicity for new mutations that were not found in the database was determined and categorized using prediction tools like SIFT, alignGVGD, mutation taster.

Statistical analysis {#s4_6}
--------------------

The non-parametric Mann-Whitney *U* test or Kruskal--Wallis test were applied to test for statistical significance between two groups or more than two groups, respectively. For parametric sample sets student's two-tailed *t*-test was applied to test for statistical significance between two groups. The correlations between *PD-1*, *PD-L1* and *IFNγ* mRNA expression were assessed by Spearman rank correlation analyses (log-transformed data were analyzed by Pearson's correlation analyses). Progression free survival (PFS) was defined as the time from diagnosis of the primary to tumor to the histopathological confirmation of recurrence or metastases and overall survival (OS) as the time from diagnosis of the primary to tumor to death from any cause or to the last clinical inspection. Univariate Kaplan-Meier analyses and multivariable Cox survival analyses were used to explore the association of *PD-1* and *PD-L1* expression with PFS and OS (the *p*-value cut-off for inclusion to the multivariable Cox analysis was 0.2). For survival analyses, patients were dichotomized into low and high mRNA expression level groups by the optimal cut-off expression value calculated by the Youden's index \[[@R17]\]. *P*-values less than 0.05 were considered as statistically significant. Statistical analysis was performed using SPSS statistical software (version 20.0.0; SPSS Inc., Chicago, IL, USA).

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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